Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 11

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 3
Chunk 11
---
 expenditure requirements for the next 12 months, we do not anticipate generating significant revenues from operations in the near future outside of the Symrise AG distribution arrangement. Moreover, we currently have no committed sources of capital.
 

13
--
 

We may attempt to raise additional funds through public or private financings, collaborations with other pharmaceutical companies or from other sources, including, without limitation, through at-the-market offerings and issuances of securities. Additional funding may not be available on terms that are acceptable to us. If adequate funding is not available to us on reasonable terms, we may need to delay, reduce or eliminate our product development programs or obtain funds on terms less favorable than we would otherwise accept. To the extent that additional capital is raised through the sale of equity securities or securities convertible into or exchangeable or exercisable for equity securities, the issuance of those securities would result in dilution to our shareholders. Moreover, the incurrence of debt financing or the issuance of dividend-paying preferred shares, could result in a substantial portion of our future operating cash flow, if any, being dedicated to the payment of principal and interest on such indebtedness or the payment of dividends on such preferred shares and could impose restrictions on our operations and on our ability to make certain expenditures and/or to incur additional indebtedness, which could render us more vulnerable to competitive pressures and economic downturns.
 
Our future capital requirements are substantial and may increase beyond our current expectations depending on many factors, including, but not limited to, the following:
 

●      the duration of changes to and results of our clinical trials for any    
                           future products going forward;                       
--------------------------------------------------------------------------------
●   unexpected delays or developments in seeking regulatory approvals,          
    as applicable;                                                              
●   the time and cost involved in preparing, filing, prosecuting, maintaining   
    and enforcing patent claims;                                                
●   unexpected developments encountered in implementing our business development
    and commercialization strategies;                                           
●   the potential addition of commercialized products to our portfolio,         
    including marketing and launch costs related to new product offerings;      
●   the outcome of future litigation; and                                       
●   further arrangements, if any, with collaborators.                           
 
In addition, global economic and market conditions, as well as future developments in the credit and capital markets, may make it even more difficult for us to raise additional financing in the future.
 
We are and will be subject to stringent ongoing government regulation for our products and our product candidates, even if we obtain applicable regulatory approvals.
 
The manufacturing, marketing and sale of